Company profile

Robert A. Bradway
Fiscal year end
Former names
IRS number

AMGN stock data



29 Oct 20
3 Dec 20
31 Dec 20


Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from AMGEN earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
9 Nov 20 Williams R Sanders Common Stock Sell Dispose S Yes 242.4 250 60.6K 4,909
2 Nov 20 Kullman Ellen Jamison Common Stock Grant Aquire A No 0 140.775 0 6,846.072
2 Nov 20 Gordon Murdo Common Stock Payment of exercise Dispose F No 216.94 6,269 1.36M 32,036
2 Nov 20 Linda H. Louie Common Stock Grant Aquire A No 0 1,453 0 7,632
2 Nov 20 David M Reese Common Stock Payment of exercise Dispose F No 216.94 2,125 461K 39,619
75.2% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2053 2035 +0.9%
Opened positions 140 167 -16.2%
Closed positions 122 117 +4.3%
Increased positions 818 754 +8.5%
Reduced positions 761 815 -6.6%
13F shares
Current Prev Q Change
Total value 111.96B 105.08B +6.5%
Total shares 437.76M 445.25M -1.7%
Total puts 3.67M 3.83M -4.1%
Total calls 4.12M 3.33M +23.8%
Total put/call ratio 0.9 1.2 -22.5%
Largest owners
Shares Value Change
BLK Blackrock 47.99M $12.2B -1.5%
Vanguard 47.94M $12.18B -1.9%
Capital Research Global Investors 33.5M $8.51B +0.4%
STT State Street 31.28M $7.95B +19.1%
Primecap Management 17.41M $4.42B -3.1%
FMR 14.2M $3.61B -16.9%
Geode Capital Management 9.17M $2.33B -8.5%
MS Morgan Stanley 8.57M $2.18B +7.0%
JPM JPMorgan Chase & Co. 8.27M $2.05B +20.2%
NTRS Northern Trust 8.14M $2.07B +2.0%
Largest transactions
Shares Bought/sold Change
STT State Street 31.28M +5.02M +19.1%
Nordea Investment Management Ab 3.36M -5M -59.8%
FMR 14.2M -2.89M -16.9%
JPM JPMorgan Chase & Co. 8.27M +1.39M +20.2%
Renaissance Technologies 573.28K -1.04M -64.4%
Capital International Investors 3.1M -1.01M -24.6%
Vanguard 47.94M -929.11K -1.9%
IVZ Invesco 3.18M +861.77K +37.1%
Geode Capital Management 9.17M -857.16K -8.5%
GS Goldman Sachs 2.1M -824.08K -28.2%

Financial report summary

Management Discussion
  • Future sales of our products will depend in part on the factors discussed in the Overview, Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition, in Part I, Item 1A. Risk Factors, and any additional factors discussed in the individual product sections below. In addition, for a list of our products’ significant competitors, see Part I, Item 1. Business—Marketing, Distribution and Selected Marketed Products—Competition.
  • The increase in ENBREL sales for 2019 was driven primarily by favorable impacts from changes in accounting estimates of sales deductions and an increase in net selling price, offset partially by lower unit demand. For 2020, we expect the trend of lower unit demand to continue.
  • The decrease in ENBREL sales for 2018 was driven primarily by lower unit demand and net selling price.
Content analysis ?
H.S. junior Avg
New words: accreted, aforementioned, aggressive, altered, attack, audit, bear, Blaylock, BNP, BofA, boosting, buildup, cardiovascular, cell, certiorari, compounded, cutoff, dealer, death, Deutsche, dispute, DKd, docetaxel, ecosystem, enduring, England, expansion, featured, hazard, HHS, interpretation, intervene, Journal, laboratory, lose, Mankind, median, MM, Morgan, mutation, newly, NSCLC, opposed, ORR, owed, predominantly, promising, published, ransomware, RBC, recommenced, recruiting, recruitment, recurrent, regimen, repeal, Run, secondary, Servier, Shank, Siebert, Slate, solid, system, text, thereof, titled, topline, underemployment, underway, uninsured, validly, Van, weekly, writ
Removed: aggregated, benchmark, Cipla, complaint, convertase, covered, denial, draft, France, Genentech, Germany, Graham, granted, Hope, infringed, involvement, Island, Japan, Jonathan, Kabi, Kingdom, noninfringement, patentability, proprotein, pursuing, Rhode, stipulation, swissbiosim, upholding, valid


Injector and method of assembly
1 Dec 20
An injector may include a container having a wall with an interior surface defining a closed sterile reservoir filled with a drug product.
Interleukin-2 muteins for the expansion of T-regulatory cells
1 Dec 20
Provided herein are IL-2 muteins, IL-2 mutein Fc-fusion molecules, anti-IL-2 antibodies, and complexes comprising an anti IL-2 antibody bound to an IL-2 cytokine that preferentially expand and activate T regulatory cells and are amenable to large scale production.
Antibody constructs for CD70 and CD3
1 Dec 20
The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell.
Solid State Forms
26 Nov 20
The present disclosure provides crystalline and amorphous forms of 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(2-propanyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(2-propenoyl)-1-piperazinyl)pyrido[2,3-d]pyrimidin-2(1H)-one, including several anhydrous, hydrate and solvate forms, and solid state forms thereof, pharmaceutical compositions, and methods of treating a disease mediated by KRAS G12C inhibition.
Methods for the Treatment of Diseases Ameliorated by PDE4 Inhibition Using Dosage Titration of Apremilast
26 Nov 20
Methods of treating, managing or preventing diseases ameliorated by inhibiting PDE4 such as psoriasis, ankylosing spondylitis, Behcet's disease, rheumatoid arthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis are disclosed.